• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

    84.39 -1.16 (-1.36%)
    Streaming Delayed Price Updated: 12:08 PM EDT, Jul 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 752,151
    Open 85.49
    Bid (Size) 84.29 (300)
    Ask (Size) 84.39 (100)
    Prev. Close 85.55
    Today's Range 84.07 - 85.71
    52wk Range 42.09 - 93.42
    Shares Outstanding 160,500,999
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
    Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals. 
    Via MarketBeat

    Performance

    YTD
    +7.9%
    +7.9%
    1 Month
    +17.2%
    +17.2%
    3 Month
    +21.1%
    +21.1%
    6 Month
    +8.4%
    +8.4%
    1 Year
    +82.5%
    +82.5%

    More News

    Read More
    News headline image
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump ↗
    Via Chartmill
    News headline image
    Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
    Via The Motley Fool
    News headline image
    BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches ↗
    Via MarketBeat
    News headline image
    BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio (BBIO) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio to Participate in May and June Investor Conferences
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio (BBIO) Q2 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
    Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
    What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
    BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
    The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
    What is the current price of BridgeBio Pharma, Inc. - Common Stock?
    The current price of BridgeBio Pharma, Inc. - Common Stock is 84.39
    When was BridgeBio Pharma, Inc. - Common Stock last traded?
    The last trade of BridgeBio Pharma, Inc. - Common Stock was at 07/29/26 12:08 PM ET
    What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
    The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 13.54B
    How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
    BridgeBio Pharma, Inc. - Common Stock has 14B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.